Figure 6.

Preliminary radiographic data from the ATTRACT (Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy) study, indicating the superiority of infliximab plus methotrexate over methotrexate alone in patients who did and did not achieve an ACR20 (that is, ACR20 responders and non-responders). ACR20 is a more than 20% improvement in tender and swollen joint counts and at least three of the following disease activity variables: the patient's assessment of pain, the patient's global assessment of disease activity, the physician's global assessment of disease activity, the patient's assessment of physical function, and the erythrocyte sedimentation rate or C-reactive protein level. *P < 0.05 versus placebo. Data on file, Centocor, Inc., Malvern, PA, USA.

Yocum Arthritis Res Ther 2004 6(Suppl 2):S24-S30   doi:10.1186/ar997